TITLE

Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma

AUTHOR(S)
Reardon, David A.; Quinn, Jennifer A.; Rich, Jeremy N.; Gururangan, Sridharan; Vredenburgh, James; Sampson, John H.; Provenzale, James M.; Walker, Amy; Badruddoja, Michael; Tourt-Uhlig, Sandra; Herndon II, James E.; Dowell, Jeannette M.; Affronti, Mary Lou; Jackson, Susanne; Allen, Deborah; Ziegler, Karen; Silverman, Steven; Bohlin, Cindy; Friedman, Allan H.; Bigner, Darell D.
PUB. DATE
April 2004
SOURCE
Neuro-Oncology;Apr2004, Vol. 6 Issue 2, p134
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits scheduledependent, synergistic activity against malignant glioma (MG). We previously established the maximum tolerated dose of CPT-11 when administered for 4 consecutive weeks in combination with BCNU administered on the first day of each 6-week cycle. We now report a phase 2 trial of BCNU plus CPT-11 for patients with MG. In the current study, BCNU (100 mg/m²) was administered on day 1 of each 6-week cycle. CPT-11 was administered on days 1, 8, 15, and 22 at 225 mg/m² for patients receiving CYP3A1- or CYP3A4-inducing anticonvulsants and at 125 mg/m² for those not on these medications. Newly diagnosed patients received up to 3 cycles before radiotherapy, while recurrent patients received up to 8 cycles. The primary end point of this study was radiographic response, while time to progression and overall survival were also assessed. Seventy-six patients were treated, including 37 with newly diagnosed tumors and 39 with recurrent disease. Fifty-six had glioblastoma multiforme, 18 had anaplastic astrocytoma, and 2 had anaplastic oligodendroglioma. Toxicities (grade ⩾3) included infections (13%), thromboses (12%), diarrhea (10%), and neutropenia (7%). Interstitial pneumonitis developed in 4 patients. Five newly diagnosed patients (14%; 95% CI, 5%–29%) achieved a radiographic response (1 complete response and 4 partial responses). Five patients with recurrent MG also achieved a response (1 complete response and 4 partial responses; 13%; 95% CI, 4%–27%). More than 40% of both newly diagnosed and recurrent patients achieved stable disease. Median time to progression was 11.3 weeks for recurrent glioblastoma multiforme patientsand 16.9 weeks for recurrent anaplastic astrocytoma/ anaplastic oligodendroglioma patients. We conclude that the activity of BCNU plus CPT-11 for patients with MG appears comparable to that of CPT-11 alone and may be more toxic.
ACCESSION #
17274061

 

Related Articles

  • 5. Automated analysis of 1p/19q status by FISH in oligodendroglial tumours. Gould, P.V.; Duval, C.; de Tayrac, M.; Sanschagrin, F.; Michaud, K.; Saikali, S. // Canadian Journal of Neurological Sciences;Aug2015 Supplement, Vol. 42 Issue S2, pS3 

    Automated analysis of 1p and 19q status in oligodendroglial tumors by fluorescence in-situ hybridization (FISH) can be achieved by image-analysis software present in the majority of institutions using the FISH technique. Despite the widespread availability of this software, there are no specific...

  • Glioblastoma and Other Malignant Gliomas. Omuro, Antonio; DeAngelis, Lisa M. // JAMA: Journal of the American Medical Association;10/30/2013, Vol. 310 Issue 17, p1842 

    IMPORTANCE Glioblastomas and malignant gliomas are the most common primary malignant brain tumors, with an annual incidence of 5.26 per 100 000 population or 17 000 new diagnoses per year. These tumors are typically associated with a dismal prognosis and poor quality of life. OBJECTIVE To review...

  • Automated Network Analysis Identifies Core Pathways in Glioblastoma. Cerami, Ethan; Demir, Emek; Schultz, Nikolaus; Taylor, Barry S.; Sander, Chris // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: Glioblastoma multiforme (GBM) is the most common and aggressive type of brain tumor in humans and the first cancer with comprehensive genomic profiles mapped by The Cancer Genome Atlas (TCGA) project. A central challenge in large-scale genome projects, such as the TCGA GBM project,...

  • Incorporating BCNU Wafers into Malignant Glioma Treatment. Balossier, Anne; Dörner, Lutz; Emery, Evelyne; Heese, Oliver; Mehdorn, H. Maximilian; Menei, Philippe; Singh, Jagmohan // Clinical Drug Investigation;2010, Vol. 30 Issue 3, p195 

    Carmustine (BCNU: N,N′-bis[2-chloroethyl]-N-nitrosourea) wafers are a local chemotherapeutic agent for the treatment of malignant glioma. They avoid the problems of high toxicity and short half-life associated with systemic delivery, and can bridge the traditional 'treatment gap' between...

  • Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Prados, Michael D.; Lamborn, Kathleen R.; Chang, Susan; Burton, Eric; Butowski, Nicholas; Malec, Mary; Kapadia, Ami; Rabbitt, Jane; Page, Margaretta S.; Fedoroff, Ann; Dong Xie; Kelley, Sean K. // Neuro-Oncology;Jan2006, Vol. 8 Issue 1, p67 

    The purpose of this study was to define the maximum tolerated dose of erlotinib and characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and without enzyme-inducing antiepileptic drugs (EIAEDs), in patients with malignant gliomas. Patients with stable or...

  • APPRENDI v. NEW JERSEY: certiorari to the supreme court of new jersey.  // Supreme Court Cases: The Twenty-first Century (2000 - Present);2009, p1 

    The article presents information on U.S. Supreme Court case Apprendi v. New Jersey, case number 99-478, argued on March 28, 2000 and decided on June 26, 2000. The petitioner was charged under New Jersey law with inter alia, second-degree possession of a firearm for an unlawful purpose when he...

  • Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. Yu Liang; Bollen, Andrew W; Aldape, Ken D; Gupta, Nalin // BMC Cancer;2006, Vol. 6, p97 

    Background: We previously identified brain type fatty acid-binding protein (FABP7) as a prognostic marker for patients with glioblastoma (GBM). Increased expression of FABP7 is associated with reduced survival. To investigate possible molecular mechanisms underlying this association, we compared...

  • Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.  // Molecular Cancer;2012, Vol. 11 Issue 1, p32 

    The article cites a research study analyzes the role of galectin-1, a gene preferentially expressed at the tumor margin, in glioblastoma cell invasion. High-grade gliomas, including glioblastomas (GBMs) are able to invade the normal brain parenchyma surrounding them and so are recalcitrant to...

  • Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Carpentier, Alexandre; Laigle-Donadey, Florence; Zohar, Sarah; Capelle, Laurent; Behin, Anthony; Tibi, Annick; Martin-Duverneull, Nadine; Sanson, Marc; Lacomblez, Lucette; Taillibert, Sophie; Puybasset, Louis; van Effenterre, Remy; Delatire, Jean-Yves; Carpentier, Antoine F. // Neuro-Oncology;Jan2006, Vol. 8 Issue 1, p60 

    Oligodeoxynucleotides containing CpG motifs (CpG ODNs) display a strong immunostimulating activity and drive the immune response toward the Th1 (T helper type 1) phenotype. These ODNs have shown promising efficacy in preclinical studies when injected locally in several cancer models. We...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics